Esperion Therapeutics, Inc.

NasdaqGM:ESPR Stock Report

Market Cap: US$496.5m

Esperion Therapeutics Management

Management criteria checks 3/4

Esperion Therapeutics' CEO is Sheldon Koenig, appointed in May 2021, has a tenure of 3.5 years. total yearly compensation is $2.97M, comprised of 24.3% salary and 75.7% bonuses, including company stock and options. directly owns 0.087% of the company’s shares, worth $431.48K. The average tenure of the management team and the board of directors is 2.7 years and 3.3 years respectively.

Key information

Sheldon Koenig

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage24.3%
CEO tenure3.5yrs
CEO ownership0.09%
Management average tenure2.7yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Nov 13

Esperion Therapeutics: Strategically Positioned To Grow

Aug 16

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

May 20

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Feb 28

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Jan 22

Esperion Is Sitting On A Potential Blockbuster Drug

Jan 14

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Jun 19
Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Mar 09
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Feb 23
Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Aug 26

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Aug 09

Esperion Therapeutics Q2 2022 Earnings Preview

Aug 01

Esperion Therapeutics: 2021 Labors Paying Off In 2022

May 07

Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout

Feb 24

Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022

Jan 20

Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection

Oct 27

Esperion: Hunting Big Game In The Danger Zone

Aug 05

CEO Compensation Analysis

How has Sheldon Koenig's remuneration changed compared to Esperion Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$87m

Jun 30 2024n/an/a

-US$98m

Mar 31 2024n/an/a

-US$87m

Dec 31 2023US$3mUS$721k

-US$209m

Sep 30 2023n/an/a

-US$208m

Jun 30 2023n/an/a

-US$222m

Mar 31 2023n/an/a

-US$239m

Dec 31 2022US$4mUS$683k

-US$234m

Sep 30 2022n/an/a

-US$243m

Jun 30 2022n/an/a

-US$258m

Mar 31 2022n/an/a

-US$235m

Dec 31 2021US$8mUS$566k

-US$269m

Sep 30 2021n/an/a

-US$308m

Jun 30 2021n/an/a

-US$325m

Mar 31 2021n/an/a

-US$156m

Dec 31 2020US$508kUS$23k

-US$144m

Compensation vs Market: Sheldon's total compensation ($USD2.97M) is above average for companies of similar size in the US market ($USD2.14M).

Compensation vs Earnings: Sheldon's compensation has been consistent with company performance over the past year.


CEO

Sheldon Koenig (58 yo)

3.5yrs

Tenure

US$2,968,565

Compensation

Mr. Sheldon L. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and had been its Chief Operating Officer since December 15, 2020 until May 1...


Leadership Team

NamePositionTenureCompensationOwnership
Sheldon Koenig
President3.5yrsUS$2.97m0.087%
$ 431.5k
Eric Warren
Chief Commercial Officer2.7yrsUS$1.08m0.082%
$ 409.1k
Benjamin Halladay
Chief Financial Officer2yrsno data0.12%
$ 614.7k
Glenn Brame
Chief Technical Operations Officer1.8yrsno datano data
Benjamin Looker
General Counsel & Corporate Secretary2.8yrsUS$1.29m0.093%
$ 462.8k
Tiffany Aldrich
Associate Director of Corporate Communicationsno datano datano data
Betty Swartz
Chief Business Officerno datano datano data

2.7yrs

Average Tenure

52yo

Average Age

Experienced Management: ESPR's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sheldon Koenig
President3.5yrsUS$2.97m0.087%
$ 431.5k
Nicole Vitullo
Lead Independent Director16.6yrsUS$94.78k0.016%
$ 80.0k
Alan Fuhrman
Independent Non-Employee Director4.7yrsUS$104.78k0.027%
$ 134.6k
Antonio Gotto
Independent Director10.8yrsUS$82.28k0.026%
$ 130.0k
Jay Shepard
Independent Director6.5yrsUS$97.28k0.026%
$ 130.0k
Stephen Rocamboli
Independent Director2.6yrsUS$94.78k0.018%
$ 91.4k
J. Carroll
Independent Chairperson2.4yrsUS$117.28k0.033%
$ 162.9k
Peter Libby
Member of Scientific Advisory Board2.3yrsno datano data
Seth H. Fischer
Independent Director3.1yrsUS$99.78k0.014%
$ 71.0k
Tracy Woody
Independent Director5.5yrsUS$91.97k0.014%
$ 71.6k
Erin Bohula
Member of Scientific Advisory Board2.3yrsno datano data
Jeffrey Bender
Member of Scientific Advisory Board2.3yrsno datano data

3.3yrs

Average Tenure

67yo

Average Age

Experienced Board: ESPR's board of directors are considered experienced (3.3 years average tenure).